An anonymous director reports

VENTRIPOINT ANNOUNCES CHANGES TO THE BOARD OF DIRECTORS

Ventripoint Diagnostics Ltd. has made changes to the board of directors.

With the recent appointment of Hugh MacNaught as interim chief executive officer and president, the composition of board committees has been adjusted as follows:

• Nominating and corporate governance committee: Dr. George Adams (chair), Robert Hodgkinson, Mr. MacNaught;
• Compensation committee: Fiona Fitzgerald, Randy Aucoin;
• Audit committee: Mr. Hodgkinson (chair), Mr. Aucoin, Dr. Adams.

Further, Dr. Alvira Macanovic has resigned as a director of the company, effective Feb. 12, 2024. The company thanks her for her service and wishes her success in her future endeavours.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.